Fludarabine
Recurrent High Grade Ovarian Serous Adenocarcinoma
M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Recurrent High Grade Ovarian Serous Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LENVATINIB M.D. Anderson Cancer Center | Phase 2 | CCC |
Lifileucel M.D. Anderson Cancer Center | Phase 2 | CCC |
Epirubicin M.D. Anderson Cancer Center | Phase 2 | CCC |
Pembrolizumab M.D. Anderson Cancer Center | Phase 2 | CCC |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 2 | CCC |
Olaparib National Cancer Institute (NCI) | Phase 1 | CC |
Onalespib National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →